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myocardial infarction, stent thrombosis, TVR).
Results: The DES and BMS groups were well matched except that DES patients
received dual antiplatelet therapy for a longer duration and had smaller final vessel
diameter. In survival analysis, at a mean follow-up of 1333 ± 659 days after PCI, the
DES group had similar incidence of death/myocardial infarction (24 vs 27%, log rank
p=0.23) and stent thrombosis (4.0 vs 2.6%, p=0.18) as the BMS group. The DES
patients had lower incidence of TVR (8.1 vs 17%, p=0.0018) but similar MACE (26
vs 37%, p=0.31). In multivariable analysis, DES vs BMS implantation showed no
significant impact on death/myocardial infarction [adjusted hazards ratio (HR) 1.0,
95% confidence intervals (CI) 0.7-1.4], stent thrombosis (HR 1.7; CI 0.7-4.0), or
MACE (HR 0.8; CI 0.6-1.1). However, TVR was lower in the DES group (HR 0.4; CI
0.3-0.7).
Conclusion: In patients presenting with NSTEMI, DES implantation appears to be as
safe as BMS implantation at long-term follow up.
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Background: There were no published data regarding the clinical efficacy and safety
of second generation drug-eluting stent (everolimus-eluting stent, EES) following
primary percutaneous coronary intervention (PCI) in ST-elevation myocardial
infarction (STEMI). We evaluated the one-year outcome of everolimus-eluting stent
versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES)
and 2nd generation (zotarolimus-eluting stent) drug-eluting stents(DES) for the
treatment of STEMI.
Methods: A prospective, open-labeled, multi-center cohort has been performed at 4
centers in Korea. All patients will be clinically followed-up for two years. The primary
endpoint was major adverse cardiac event (MACE): the composite of cardiac death
(CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1
year. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 797 patients (EES=197, ZES=203, SES=203, PES=194) who were
completed more than one year were analyzed. One-year MACE were 2.0%, 5.9%,
3.4% and 5.7% in EES-, ZES-, SES- and PES-group, respectively (p=ns). Cardiac
death was 1.0%, 2.5%, 1.5% and 1.0% in EES-, ZES-, SES- and PES-group,
respectively (p=ns). ST was 0%, 2.0%, 2.0% and 2.0% in EES-, ZES-, SES- and PES-
group, respectively (p=ns).
Clinical events at 12 months and stent thrombosis
EES : everolimus-eluting stent, ZES : zotalimus-eluting stent, SES : sirolimus-
eluting stent, PES : paclitaxel-eluting stent, MACE : major adverse cardiac event,
MI : myocardial infarctin, TLR : target lesion revascularization
Conclusion: Campared to 1st and 2nd generation DES (SES and PES, ZES), EES
showed similar one-year clinical outcomes in terms of MACE in patients with STEMI
following primary PCI and no stent thrombosis.
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Background: The concept and possible benefit of complete revascularisation of all
detected lesions in patients with multivessel disease during one PCI procedure using
drug eluting stents (DES) is under debate. We compared long term clinical outcomes
of complete and incomplete revascularisation in patients with multivessel disease when
treated with a new generation DES coated only abluminally with biodegradable
polymer and Biolimus A9.
Methods: Among 3067 consecutive patients treated with Nobori DES, and enrolled
in NOBORI2 study, 1788 patients had multivessel disease out of which 593 underwent
complete revascularization (complete-PCI) and 1195 received treatment of most critical
lesions (incomplete-PCI). The primary endpoint of the study was target lesion failure
(TLF), a composite of cardiac death, target vessel related MI and target lesion
revascularization (TLR) at 1 year. Data are entered in an electronic database; all adverse
events are adjudicated by an independent clinical event committee and all angiograms
are analyzed by an independent corelab.
Results: Complete-PCI patients were younger and had less often previous CABG,
hypertension and ACS. Number of diseased vessels and detected lesions was
significantly lower in the complete-PCI group but the number of treated vessels and
stents implanted was significantly higher. Lesion complexity was similar in both groups
with more thrombotic lesions in patients with incomplete-PCI. Among QCA assessed
parameters, lesions were shorter with lower diameter stenosis pre-procedure in
complete-PCI group. At 2 year follow-up TLF rate was slightly higher in the complete-
PCI group (6.6% vs 5.5%; p=0.4) while non-TVR rate was lower (2.2% vs 5.6%;
p<0.001). Stent thrombosis was low in both groups (1.0% vs 1.1% incomplete-PCI;
p=NS).
Conclusion: Despite higher number of stents implanted in the complete-PCI group,
TLF was comparable with the incomplete-PCI group at 2 years. Therefore selective
revascularization strategy of the most critical lesions (followed by deferred
revascularization of some non-treated lesions) in higher risk patients is safe and results
in a favorable outcome.
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Background: Implantation of drug eluting stents (DES) tends to be implanted in
complex lesion compared with bare metal stents era. Preservation of integrity of
polymer coating in these complex lesions is an important.
Methods: Taxus LibertéTM, Endeavor SprintTM, Xience VTM, Cypher SelectTM
and NoboriTM DES (five samples of each) were explored by scanning electron
microscopy (SEM) following expansion at nominal pressure. In addition to simple
expansion, a part of samples were tasked through the 5 or 6 French catheter with a
parallel wire in order to stimulate the injury. We classified DES coating damage into
four groups which were irregularities (Type I), cracks (Type II), craters with metal
exposure (Type III) and webbings (Type IV). Each DES showed specific feature of
abnormalities in polymer coating such as webbing in Taxus LibertéTM, craters in
Endeavor SprintTM and minor cracks in NoboriTM.
Results: After the injuries, craters with metal exposure were slightly increased in
NoboriTM, Xience VTM, while it was largely increased in Endeavor SprintTM. The
damage of polymer coating by the creation of injury was minimal Taxus LibertéTM.
The craters with metal exposure were seen in all types of DES. Among them, the
incidence of areas with bare metal exposure was particularly low in NoboriTM, Xience
VTM and Cypher SelectTM. Endeavor SprintTM showed the largest metal exposure
with scratch. Webbings of the coating were found in Taxus LibertéTM, while they were
not seen in Endeavor SprintTM.
The incidence of coating abnormality in all population
Conclusion: The incidence of various coating irregularities in different types of DES
varied widely. These data give us insight into the choice of DES especially in complex
lesions.
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Background: Randomized clinical trials showed safety and efficacy of everolimus-
eluting stents in selected patient populations. However, since the approval of
second-generation stents in the US, limited data are available with regard to their safety
and efficacy in unselected, consecutive patients.
Methods: Consecutive patients at Washington Hospital Center who underwent
coronary artery stent implantation with Xience, Taxus or Cypher stents were analyzed.
Patients who received other stent types were excluded. Analyzed clinical end points
were death, TLR, definite stent thrombosis (ST), and MACE (death, QWMI, or TLR)
at 1 year.
Results: A total of 5983 patients received DES. Xience patients had higher rates of
hypertension (89% vs. 86% vs. 85% respectively; p=0.003) and diabetes (40% vs. 35%
vs. 35%; p=0.03) but lower rates of family history of CAD (47% vs. 53% vs. 52%;
p=0.008) as compared with Cypher and Taxus. Nearly half of the patients had PCI for
unstable angina (51% vs. 43% vs. 45%, p <0.001) and treated lesions were more likely
to be Type C among Xience patients (47% vs. 21% vs. 23%; p <0.001). Unadjusted 1-
year MACE (8.1% vs. 9.6% vs. 11.2%) and all-cause mortality (3.4% vs. 4.8% vs.
6.9%) were significantly lower for Xience patients compared with Taxus but not to
Cypher patients. (Figure) Definite ST and TLR rates were non-significantly lower for
Xience patients as compared with Cypher or Taxus patients. (Figure) After adjusting
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